Categories
Change Password!
Reset Password!
Probiotic nasal spray containing S. salivarius 24SMB and S. oralis 89a could be beneficial in managing the symptoms associated with chronic adenoiditis in pediatric patients.
In a recent study issued in the "European Journal of Pediatrics", probiotic nasal treatment, utilizing S. salivarius 24SMB and S. oralis 89a, illustrated a positive effect in reducing the blockage of the nasopharynx space caused by hypertrophic adenoids in children (aged 2-18 years) suffering from chronic adenoiditis. Chronic adenoiditis, a condition often caused by infectious foci in the nasopharynx, has long posed challenges in effective management. Hence, this prospective, double-blind, randomized controlled trial assessed the efficacy and safety of a 90-day treatment with a probiotic nasal spray containing S. salivarius 24SMB and S. oralis 89a.
Children with chronic adenoiditis were given one puff in each nostril twice a day, and the results were compared with a nasal spray placebo. The key endpoint focused on the decrease in acute adenoidal infections number, while the secondary endpoint evaluated the obstruction of the nasopharynx space by hypertrophic adenoids. The final analysis included 152 children, with males comprising 48.0% and a mean age of 49.2 ± 14.1 months. No profound differences in the number of acute exacerbations were observed between the study and control groups at the T1 (90 days after recruitment) and T2 (90 days after treatment suspension) follow-up visits compared to the baseline.
However, the study group exhibited a profound drop in the occlusion of the nasopharynx space by hypertrophic adenoids at both T1 and T2 in comparison with baseline. Hence, topical nasal use of a probiotic compound containing S. salivarius 24SMB and S. Oralis 89a appears to be a valuable addition to the integrated therapeutic management of pediatrics battling chronic adenoiditis.
European Journal of Pediatrics
Topical administration of S. Salivarius 24SMB-S. oralis 89a in children with adenoidal disease: a double-blind controlled trial
Francesco Folino et al.
Comments (0)